Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malaria

Free Subscription Articles published in Vaccine Retrieve available abstracts of 37 articles: HTML format

Single Articles

May 2026
1. POURHASHEM Z, Siasi S, Nourani L, Yousefi H, et al
   Multi-antigen transmission-blocking malaria vaccine elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi.
   Vaccine. 2026;84:128683.
   PubMed     Abstract available
   
   
   April 2026
2. GOTHAM D, Frick M, Harrington M
   Understanding adjuvant supply chains for new TB and malaria vaccines.
   Vaccine. 2026;82:128609.
   PubMed    
   
   
   
3. LAURENSON AJ, Pierce BG, Takala-Harrison S, Laurens MB, et al
   TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.
   Vaccine. 2026;77:128388.
   PubMed     Abstract available
   
   
   March 2026
4. D'ALESSIO F, Honkpehedji J, Sirima S, Gamain B, et al
   Immunization strategies to prevent malaria in pregnancy - a multistakeholder workshop.
   Vaccine. 2026;79:128505.
   PubMed     Abstract available
   
   
   February 2026
5. KRETCHY IA, Bonful HA, Opoku-Mireku M, Koduah A, et al
   Impact of caregivers' perceptions of malaria on their hesitancy toward childhood malaria vaccination.
   Vaccine. 2026;77:128389.
   PubMed     Abstract available
   
   
   
6. AL-ABBOODI A, Falih IQ, Al-Asadi M, Hussein BA, et al
   Iron-oxide nanoparticles (SPIONs) enhance malaria vaccine antibody response.
   Vaccine. 2026;77:128353.
   PubMed     Abstract available
   
   
   January 2026
7. HONG H, Eom TH, Lee E, Lee E, et al
   Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant.
   Vaccine. 2026;75:128279.
   PubMed     Abstract available
   
   
   December 2025
8. PINANDYO SH, Ali S, Aurelio B, Amoah AS, et al
   The association of helminth infection against antimalarial antibody responses in malaria infection and vaccination: a systematic review and meta-analysis.
   Vaccine. 2025;73:128125.
   PubMed     Abstract available
   
   
   November 2025
9. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
   Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
   Vaccine. 2025;69:127973.
   PubMed    
   
   
   
10. BIRKETT AJ, Ansah E, Gordon S, Gyapong M, et al
    Value profile for Malaria vaccines and monoclonal antibodies.
    Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971.
    PubMed     Abstract available
    
    
    
11. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
    Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.
    Vaccine. 2025;68:127897.
    PubMed     Abstract available
    
    
    October 2025
12. ANOSIKE C, Ojiakor IM, Etiaba EI, Uguru NP, et al
    Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.
    Vaccine. 2025;67:127853.
    PubMed     Abstract available
    
    
    
13. BELMONTE M, Kusi KA, Kyei-Baafour E, Ofori EA, et al
    Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology.
    Vaccine. 2025;66:127832.
    PubMed     Abstract available
    
    
    September 2025
14. ZHAO Z, Ma X, Milligan P, Cheung YB, et al
    Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
    Vaccine. 2025;63:127673.
    PubMed     Abstract available
    
    
    July 2025
15. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
    Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
    Vaccine. 2025;60:127323.
    PubMed     Abstract available
    
    
    June 2025
16. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
    Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
    Vaccine. 2025;61:127376.
    PubMed     Abstract available
    
    
    May 2025
17. YUN SY, Nguyen MN, Hong H, Bae GJ, et al
    Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii.
    Vaccine. 2025;55:127032.
    PubMed     Abstract available
    
    
    April 2025
18. PARVEEN S, Rath PP, Tabrez S, Khan S, et al
    Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.
    Vaccine. 2025;54:126993.
    PubMed     Abstract available
    
    
    
19. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
    Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
    Vaccine. 2025;53:127076.
    PubMed     Abstract available
    
    
    
20. DESHMUKH B, Khatri D, Kochar SK, Athale C, et al
    In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum.
    Vaccine. 2025;53:126952.
    PubMed     Abstract available
    
    
    
21. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    PubMed     Abstract available
    
    
    February 2025
22. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
    Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
    Vaccine. 2025;50:126783.
    PubMed     Abstract available
    
    
    January 2025
23. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    PubMed     Abstract available
    
    
    October 2024
24. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    PubMed     Abstract available
    
    
    July 2024
25. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    PubMed     Abstract available
    
    
    
26. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    May 2024
27. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
28. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    April 2024
29. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    March 2024
30. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    February 2024
31. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
32. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    November 2023
33. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    
34. HAYASHI CTH, Cao Y, Zavala F, Simonyan H, et al
    Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences.
    Vaccine. 2023;41:6824-6833.
    PubMed     Abstract available
    
    
    August 2023
35. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    May 2023
36. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    PubMed     Abstract available
    
    
    April 2023
37. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malaria is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum